Review Article: the Role of Tumor Necrosis Factor in Renal Ischemia-reperfusion Injury
Overview
Authors
Affiliations
Renal ischemia-reperfusion injury induces a cascade of events leading to cellular damage and organ dysfunction. Tumor necrosis factor-alpha (TNF), a potent proinflammatory cytokine, is released from the kidney in response to, and has been implicated in the pathogenesis of, renal ischemia-reperfusion injury. TNF induces glomerular fibrin deposition, cellular infiltration and vasoconstriction, leading to a reduction in glomerular filtration rate (GFR). The signaling cascade through which renal ischemia-reperfusion induces TNF production is beginning to be elucidated. Oxidants released following reperfusion activate p38 mitogen activated protein kinase (p38 MAP kinase) and the TNF transcription factor, NFkappaB, leading to subsequent TNF synthesis. In a positive feedback, proinflammatory fashion, binding of TNF to specific TNF membrane receptors can reactivate NFkappaB. This provides a mechanism by which TNF can upregulate its own expression as well as facilitate the expression of other genes pivotal to the inflammatory response. TNF receptor binding can also induce renal cell apoptosis, the major form of cell death associated with renal ischemia-reperfusion injury. Anti-TNF strategies targeting p38 MAP kinase, NFkappaB, and TNF itself are being investigated as methods of attenuating renal ischemic injury. The control of TNF production and activity represents a realistic goal for clinical medicine.
Jeong K, Je J, Dusabimana T, Karekezi J, Nugroho T, Ndahigwa E Int J Mol Sci. 2024; 25(23).
PMID: 39684275 PMC: 11641314. DOI: 10.3390/ijms252312563.
Rysmakhanov M, Zare A, Smagulov A, Abenova N, Mussin N, Sultangereyev Y Curr Pharm Des. 2024; 30(20):1578-1598.
PMID: 38676525 DOI: 10.2174/0113816128283420240409050754.
Abd-Eldayem A, Makram S, Messiha B, Abd-Elhafeez H, Abdel-Reheim M Sci Rep. 2024; 14(1):7434.
PMID: 38548778 PMC: 10978894. DOI: 10.1038/s41598-024-57300-x.
The role of non-protein-coding RNAs in ischemic acute kidney injury.
Sabet Sarvestani F, Afshari A, Azarpira N Front Immunol. 2024; 15:1230742.
PMID: 38390339 PMC: 10881863. DOI: 10.3389/fimmu.2024.1230742.
Pharmacological functions of salidroside in renal diseases: facts and perspectives.
Liu Q, Chen J, Zeng A, Song L Front Pharmacol. 2024; 14:1309598.
PMID: 38259279 PMC: 10800390. DOI: 10.3389/fphar.2023.1309598.